Compare ACIC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACIC | OABI |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.2M | 300.9M |
| IPO Year | N/A | N/A |
| Metric | ACIC | OABI |
|---|---|---|
| Price | $12.88 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 121.4K | ★ 636.7K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 5.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $328,331,000.00 | $21,094,000.00 |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $2.40 | $66.19 |
| P/E Ratio | $7.51 | ★ N/A |
| Revenue Growth | ★ 22.22 | 3.36 |
| 52 Week Low | $9.97 | $1.22 |
| 52 Week High | $13.78 | $4.02 |
| Indicator | ACIC | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 55.51 |
| Support Level | $12.66 | $2.00 |
| Resistance Level | $13.06 | $2.15 |
| Average True Range (ATR) | 0.26 | 0.11 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 79.91 | 37.50 |
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.